Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?

By H. Mirghani, P. Blanchard. 2017

169 citations recorded by the source corpus.

Highlights • HPV-driven cancers have significantly better survival than traditional head and neck cancers.• Current treatments are reassessed to develop less toxic strategies with good oncological outcomes.• Treatment de-escalation raises issues such as patient selection and the benefit/risk balance.• Rigorously constructed trials leading to specific management for HPV-driven OPSCCs are mandatory.

Subfields: Genetics, Otorhinolaryngology, Surgery

Citations in the corpus

• Simulation-assisted machine learning (2018, neutral): “…amplified gene: HER2), melanoma (BRAF mutation), lung (EML4-ALK fusion) and head-and-neck (HPV status for radiation dose de-escalation; see Mirghani and Blanchard, 2017), there remains a large variability in patient responses to these and other treatments, likely due to the fact that…”